VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Mencarelli, Andrea ^a   Cipriani, Sabrina ^a   Renga, Barbara ^a   Bruno, Angela ^a   D'Amore, Claudio ^a   Distrutti, Eleonora ^b   Fiorucci, Stefano ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN SULFATE; FARNESOID X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; VITAMIN D RECEPTOR; VSL3;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA ATHEROSCLEROSIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DYSLIPIDEMIA; ENTERITIS; HISTOPATHOLOGY; INSULIN RESISTANCE; INTESTINE MUCOSA PERMEABILITY; LIVER PROTECTION; MALE; MESENTERY; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; TRANSACTIVATION; TREATMENT DURATION;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DYSLIPIDEMIAS; FATTY LIVER; INFLAMMATION; INSULIN RESISTANCE; INTESTINES; MALE; MICE; MICE, KNOCKOUT; PROBIOTICS; SIGNAL TRANSDUCTION;

MUS;

EID: 84866700091     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045425     Document Type: Article

References (67)

1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640-1645.
2. Reinhard W, Holmer SR, Fischer M, Gloeckner C, Hubauer U, et al. (2006) Association of the metabolic syndrome with early coronary disease in families with frequent myocardial infarction. Am J Cardiol 97: 964-967.
3. Loria P, Lonardo A, Carulli N, (2005) Should nonalcoholic fatty liver disease be renamed? Dig Dis 23: 72-82.
4. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H, (2007) Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 92: 3490-3497.
5. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917-923.
6. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, et al. (2005) The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143: 722-728.
7. Sanyal AJ, (2005) Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2: 46-53.
8. Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, et al. (2007) Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 13: 1579-1584.
9. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, et al. (2007) Alanine aminotransferase predicts coronary heart disease events: a 10 year follow-up of the Hoorn Study. Atherosclerosis 191: 391-396.
10. Targher G, Day CP, Bonora E, (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363: 1341-1350.
11. Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, et al. (2007) High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 42: 573-582.
12. Kotronen A, Yki-Jarvinen H, (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28: 27-38.
13. Musso G, Gambino R, Bo S, Uberti B, Biroli G, et al. (2008) Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care 31: 562-568.
14. Angulo P, (2002) Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231.
15. Day CP, (2006) Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int 26: 1021-1028.
16. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM, (1997) Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 94: 2557-2562.
17. Sakaguchi S, Takahashi S, Sasaki T, Kumagai T, Nagata K, (2011) Progression of alcoholic and non-alcoholic steatohepatitis: common metabolic aspects of innate immune system and oxidative stress. Drug Metab Pharmacokinet 26(1): 30-46.
18. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, et al. (2001) The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48: 206-211.
19. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, et al. (2009) Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49(6): 1877-1887.
20. Nair S, Cope K, Risby TH, Diehl AM, (2001) Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 96: 1200-1204.
21. Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, et al. (2006) Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A 103: 12511-12516.
22. Jacob AI, Goldberg PK, Bloom N, Degenstein GA, Kozinn PJ, (1977) Endotoxin and bacteria in portal blood. Gastroenterology 72: 1268-1270.
23. Poggi M, Bastelica D, Gual P, Iglesias MA, Gremeaux T, et al. (2007) C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia 50(6): 1267-1276.
24. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, et al. (2007) Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 56: 1986-1998.
25. Lichtman SN, Keku J, Schwab JH, Sartor RB, (1991) Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterology 100: 513-519.
26. Lichtman SN, Sartor RB, Keku J, Schwab JH, (1990) Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology 98: 414-423.
27. Ma X, Hua J, Li Z (2008) Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 49: 821-830.
28. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, et al. (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58(8): 1091-1103.
29. King VL, Hatch NW, Chan HW, de Beer MC, de Beer FC, et al. (2010) A murine model of obesity with accelerated atherosclerosis. Obesity (Silver Spring) 18(1): 35-41.
30. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barocci N, et al. (1999) Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48: 1270-1274.
31. Ewaschuk J, Endersby R, Thiel D, Diaz H, Backer J, et al. (2007) Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis. Hepatology 46: 841-850.
32. Ewaschuk JB, Diaz H, Meddings L, Diederichs B, Dmytrash A, et al. (2008) Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am J Physiol Gastrointest Liver Physiol 295: G1025-G1034.
33. Kershaw EE, Flier JS, (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 89: 2548-2556.
34. Paul G, Schäffler A, Neumeier M, Fürst A, Bataillle F, et al. (2006) Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm Bowel Dis. 12: 471-477.
35. Cheng X, Chen Y, Xie JJ, Yao R, Yu X, et al. (2008) Suppressive oligodeoxynucleotides inhibit atherosclerosis in ApoE(-/-) mice through modulation of Th1/Th2 balance. J Mol Cell Cardiol 45: 168-175.
36. Methe H, Brunner S, Wiegand D, Nabauer M, Koglin J, et al. (2005) Enhanced T helper-1 lymphocyte activation patterns in acute coronary syndromes. J Am Coll Cardiol 45: 1939-1945.
37. Xie JJ, Wang J, Tang TT, Chen J, Gao XL, et al. (2010) The Th17/Treg functional imbalance during atherogenesis in ApoE-/- mice. Cytokine 49(2): 185-193.
38. Bensinger SJ, Tontonoz P, (2008) Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454(7203): 470-477.
39. Mencarelli A, Distrutti E, Renga B, D'Amore C, Cipriani S, et al. (2011) Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One 6(7): e22978.
40. Kelly D, Campbell JI, King TP, Grant G, Jansson EA, et al. (2004) Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 5: 104-112.
41. Reiff C, Delday M, Rucklidge G, Reid M, Duncan G, et al. (2009) Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 15: 1721-1736.
42. Bassaganya-Riera J, Viladomiu M, Pedragosa M, De Simone C, Carbo A, et al. (2012) Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR γ to suppress colitis. PLoS One 7(2): e31238.
43. Abubucker S, Segata N, Goll J, Schubert AM, Izard J, et al. (2012) Metabolic reconstruction for metagenomic data and its application to the human microbiome. PLoS Comput Biol 8(6): e1002358.
44. Brown CT, Davis-Richardson AG, Giongo A, Gano KA, Crabb DB, et al. (2011) Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One 6(10): e25792.
45. Lakhdari O, Cultrone A, Tap J, Gloux K, Bernard F, et al. (2010) Functional metagenomics: a high throughput screening method to decipher microbiota-driven NF-κB modulation in the human gut. PLoS One 5(9). pii: e13092.
46. Murphy EF, Cotter PD, Healy S, Marques TM, O'Sullivan O, et al. (2010) Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 59: 1635-1642.
47. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, et al. (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464: 59-65.
48. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, et al. (2011) Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331: 337-341.
49. Ali K, Middleton M, Puré E, Rader DJ, (2005) Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ Res. 97: 922-927.
50. Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, et al. (2009) VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 49: 989-997.
51. Li Z, Yang S, Lin H, Huang J, Watkins PA, et al. (2003) Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37: 343-350.
52. Lirussi F, Mastropasqua E, Orando S, Orlando R, (2007) Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane database of systematic reviews (1): CD005165.
53. Andraws R, Berger JS, Brown DL, (2005) Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA 293: 2641-2647.
54. Stepankova R, Tonar Z, Bartova J, Nedorost L, Rossman P, et al. (2010) Absence of microbiota (germ-free conditions) accelerates the atherosclerosis in ApoE-deficient mice fed standard low cholesterol diet. J Atheroscler Thromb 17: 796-804.
55. Mencarelli A, Renga B, Migliorati M, Cipriani S, Distrutti E, et al. (2009) The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J Immunol 183: 6657-6666.
56. Fiorucci S, Cipriani S, Mencarelli A, Renga B, Distrutti E, et al. (2010) Counter-regulatory role of bile acid activated receptors in immunity and inflammation. Curr Mol Med 10(6): 579-595.
57. Menendez-Gutierrez MP, Roszer T, Ricote M, (2012) Biology and therapeutic applications of peroxisome proliferator- activated receptors. Curr Top Med Chem 12(6): 548-584.
58. Fiorucci S, Cipriani S, Baldelli F, Mencarelli A, (2010) Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res 49: 171-185.
59. Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S, (2009) The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 183(10): 6251-6261.
60. Bassaganya-Riera J, Reynolds K, Martino-Catt S, Cui Y, Hennighausen L, et al. (2004) Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 127: 777-791.
61. Mencarelli A, Cipriani S, Renga B, Francisci D, Palladino G, et al. (2010) The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. PLoS One 5(10): e13238.
62. Mencarelli A, Fiorucci S, (2010) FXR an emerging therapeutic target for the treatment of atherosclerosis. J Cell Mol Med 14(1-2): 79-92.
63. Mencarelli A, Renga B, Distrutti E, Fiorucci S, (2009) Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol 296(2): H272-281.
64. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, et al. (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2(4): 217-225.
65. Li H, Gao Z, Zhang J, Ye X, Xu A, et al. (2012) Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3. Diabetes 61(4): 797-806.
66. Fiorucci S, Cipriani S, Mencarelli A, Baldelli F, Bifulco G, et al. (2011) Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. Mini Rev Med Chem 11(9): 753-762.
67. Carlberg C, Molnár F, Mouriño A, (2012) Vitamin D receptor ligands: the impact of crystal structures. Expert Opin Ther Pat 22(4): 417-435.